Non-White New Yorkers to Receive Priority For Scarce Monoclonal Antibody Treatment
Whites need not apply.
Non-white New Yorkers will receive priority for scarce monoclonal antibody treatments and Covid oral antiviral pills.
The New York State Department of Health this week published a memo warning they don’t have enough Paxlovid or Monoclonal Antibody Treatment so white people will be put at the back of the line.
The NYSDOH said Paxlovid and Molnupiravir are in “limited supply will require providers to prioritize treatment for patients at highest risk for severe COVID-19 until more product becomes available.”
The department said it will be prioritize people who have certain risk factors for severe disease.
One of the risk factors?
Race.
“Non-white race or Hispanic/Latino ethnicity should be considered a risk factor, as longstanding systemic health and social inequities have contributed to an increased risk of severe illness and death from Covid-19,” the NYSDOH said.
How is this even legal?
How is the race or ethnicity of a patient a legitimate criterion for the allocation of scarce clinical resources (like drugs or hospital beds) by a government entity in 2021 in the USA? And how could this even be constitutional? https://t.co/m6gRlnaEX2
— Nicholas A. Christakis (@NAChristakis) December 31, 2021
